Potassium Acetate Injection
Last Updated: February 27, 2017
Status: Current
Products Affected - Description
Potassium acetate injection, American Regent
2 mEq/mL, 20 mL vial, 25 count (NDC 00517-2053-25)
4 mEq/mL, 50 mL vial, 25 count (NDC 00517-5024-25)
Reason for the Shortage
- American Regent has potassium acetate on long-term shortage due to manufacturing delays. It is unclear if and when product will return to market
- Pfizer has potassium acetate injection available.
- Exela received FDA approval for potassium acetate injection in late-December 2015. Exela has potassium acetate injection available.
Available Products
Potassium acetate injection, Exela Pharma Sciences
2 mEq/mL, 20 mL vial, 25 count (NDC 51754-2001-04)
Potassium acetate injection, Hospira
2 mEq/mL, 20 mL vial, 25 count (NDC 00409-8183-01)
2 mEq/mL, 20 mL vial, 25 count (NDC 00409-8183-01)
2 mEq/mL, 50 mL vial, 25 count (NDC 00409-3924-51)
Estimated Resupply Dates
- American Regent has potassium acetate 2 mEq/mL 20 mL vials and 4 mEq/mL 50 mL vials on long-term back order and the company cannot estimate a release date.
- All other marketed presentations are available.
Related Shortages
- Bacteriostatic Sodium Chloride for Injection 0.9% — Resolved
- Calcium Gluconate Injection — Current
- Chromium (Chromic Chloride) Injection — Resolved
- Potassium Chloride Injection — Current
- Sodium Chloride 0.9% Injection Bags — Current
Updated
February 27, 2017; December 19, October 8, September 13, August 10, July 8, June 14 and 3, April 27, March 21, February 17 and 4, January 28, 2016; December 30, 2015, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.
